BRAF mutation

P3, N=1021, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting

Multiplex immunofluorescence staining demonstrated that BCL-xL inhibition effectively triggered apoptosis in heterogeneous PDX tumor slice models, including models harboring oncogenic BRAF mutations. Our findings suggest that cetuximab-resistant CRC retains apoptotic competence, and that BCL-xL inhibition serves as a robust alternative therapeutic strategy that is largely independent of the tumor mutational profile.

P=N/A, N=34, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital

P2, N=40, Not yet recruiting, The Fourth People's Hospital of Zibo City; The Fourth People's Hospital of Zibo City

P1/2, N=120, Recruiting, Shanghai East Hospital; Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

P1, N=80, Not yet recruiting, Sun Yat-sen University Cancer Center; Degron Therapeutics

P1, N=48, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P2, N=20, Recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting --> Recruiting

No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in MSS mCRC patients treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.

Rarer alterations in KIT and RTKs also define actionable subsets. This review synthesizes recent mechanistic insights and therapeutic advances in mutation-driven melanoma, highlighting the promise of biomarker-guided combination strategies and signaling crosstalk disruption as the next frontier in precision oncology.

However, when pooling all target mutations (KRAS, NRAS and BRAF), the overall sensitivity and specificity were lower, at 48.3% and 51.1%, respectively. The results of this study indicate that the ddPCR analysis of ctDNA may provide complementary information for the molecular diagnosis of CRC patients.

The nomogram, integrating clinicopathological and genetic factors, provides a robust tool for predicting outcomes in patients with stage II-III CRC. It can aid in personalized treatment planning and improve patient management.